Levi & Korsinsky, LLP announces that an AKBA class action lawsuit has been filed on behalf of investors who purchased Akebia Therapeutics, Inc. (AKBA) securities between June 28, 2018, and September 2, 2020 For more on the AKBA Lawsuit please contact us today.  

According to the Akebia lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead investigational product candidate, vadadustat, was not as safe in treating non-dialysis dependent chronic kidney disease patients with anaemia as defendants had represented; (ii) as a result, defendants overstated the clinical prospects of Phase 3 clinical program for vadadustat; (iii) accordingly, defendants also overstated vadadustat’s overall commercial and regulatory prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE AKBA CLASS ACTION LAWSUIT, CLICK HERE 

If you suffered a loss in Akebia you have until May 13, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. 

CONTACT: 

Levi & Korsinsky, LLP 

Joseph E. Levi, Esq. 

55 Broadway, 10th Floor 

New York, NY 10006 

jlevi@levikorsinsky.com 

Tel: (212) 363-7500 

Fax: (212) 363-7171 

www.zlk.com